'Without support from the CGD Research Trust, we would not have been able to generate the preliminary results that led to this grant being funded', said award winner Dr Segal.
The National Institutes of Health (NIH) has awarded a five-year, $2.2 million dollar research grant to Roswell Park Cancer Institute (Buffalo, New York) for a proposal, entitled, 'Role of NADPH oxidase in regulating inflammation.' Brahm H. Segal, MN, Chief of Infectious Diseases at Roswell Park Cancer Institute and Associate Professor of Medicine at the School of Medicine and Biomedical Sciences at the University of Buffalo, New York, is the principal investigator. Dr Segal and colleagues from Vanderbilt University Medical Center, Timothy Blackwell, MD and Michael Freeman, PhD, will analyse the enzyme affected in CGD as a critical regulator of inflammation.
'We know, based on the experience in CGD patients, that the enzyme NADPH oxidase is required to defend against bacterial and fungal infections', said Dr Segal. 'A less understood role of this key enzyme relates to dampening down excessive inflammation, an action that could help people with CGD. Our global model is that NADPH oxidase regulates inflammation by generation of reactive oxidants that interact with down stream targets. These include factors known as NF-kB and Nrf-2, that have broad effects on inflammation. The specific aims of our grant are to understand mechanisms regarding how NADPH oxidase regulates inflammation. We hope that this knowledge will pave the way to novel therapeutic approaches for CGD.'
'I'm reorganising my lab including hiring a senior research person and graduate students.' The work also has broader implications. Dr Segal explains 'How the enzyme affected in CGD regulates inflammation is centrally relevant to CGD, but it is broadly important to disorders of inflammation such as autoimmune disorders and cancer.'
Dr Segal is a world expert on Aspergillus and is passionate about helping people with CGD. With CGD Research Tust funding he is working on developing a vaccine against fungal infections caused by Aspergillus.
'The funding provided by the charity for research is critical. I'm so grateful for the support from the CGD Research Trust.'
IMPORTANT NOTE :
The information contained on this website is intended only as a guideline, not as a substitute for medical advice. Always consult your doctor if you or your child has any CGD symptoms or concerns.
© 2001-2007 The Chronic Granulomatous Disorder (CGD) Research Trust
Registered Charity No. 1003425 email:cgd@cgdrt.co.uk
The CGD Research Trust is a member of the Association of Medical Research Charities (AMRC), the Genetic Interest Group (GiG) and an associate member of the International Patient Organisation of Primary Immunodeficiencies (IPOPI)
Site Map | Terms and Conditions | Privacy
